论文部分内容阅读
目的探讨荞麦花叶总黄酮(TFBFL)对去甲肾上腺素所致大鼠心肌肥厚的保护作用及其可能的机制。方法将大鼠随机分为6组(n=12):空白对照组,肥厚模型组,TFBFLⅠ、Ⅱ、Ⅲ组,和卡托普利治疗组(Cap组)。用去甲肾上腺素(NE)腹腔注射1.5mg/(kg·d),Bid,建立大鼠心肌肥厚模型,同时TFBFL和Cap灌胃给药100、200、400和50mg/(kg·d),o.d.,连续15d。观察心电图(ECG),左心室肥厚指数(LVWI:lvw/bw),和心重指数(HWI:hw/bw,lvw/hw)。采用比色法测定心室肌钙含量,用放免分析法检测血浆、心肌、肾脏血管紧张素Ⅰ(AngⅠ)生成率(反映肾素活性)和血管紧张素Ⅱ(AngⅡ)含量。结果与肥厚模型组比,TFBFL能剂量依赖性的改善心肌肥厚大鼠的ECG,降低LVWI和HWI,心肌钙含量和心肌AngⅡ含量,但对血浆肾脏AngⅡ含量无明显影响和心肌、血浆和肾脏AngⅠ生成率均无明显影响,且与阳性药物卡托普利组治疗效果相近。结论荞麦花叶总黄酮对大鼠心肌肥厚具有保护作用,其机制可能与拮抗心肌局部肾素-血管紧张素(RAS)系统有关。
Objective To investigate the protective effect of buckwheat mosaic flavonoids (TFBFL) on norepinephrine-induced cardiac hypertrophy in rats and its possible mechanism. Methods Rats were randomly divided into 6 groups (n=12): blank control group, hypertrophy model group, TFBFLI, II, III group, and captopril treatment group (Cap group). Norepinephrine (NE) was intraperitoneally injected with 1.5 mg/(kg·d) of Bid to establish rat cardiac hypertrophy model, while TFBFL and Cap were intragastrically administered at 100, 200, 400 and 50 mg/(kg·d). Od, continuous 15d. Electrocardiogram (ECG), left ventricular hypertrophy index (LVWI: lvw/bw), and heart weight index (HWI: hw/bw, lvw/hw) were observed. The colorimetric method was used to determine the ventricular calcium content. Radioimmunoassay was used to detect the production of angiotensin I (AngI) (reflecting renin activity) and angiotensin II (AngII) in plasma, myocardium, and kidney. Results Compared with the hypertrophic model group, TFBFL dose-dependently improved ECG of rats with myocardial hypertrophy, reduced LVWI and HWI, myocardial calcium content and myocardial AngII content, but had no significant effect on plasma AngII content in the kidney and myocardial, plasma, and kidney AngI. There was no significant effect on the rate of production, and the treatment effect was similar to that of the positive drug captopril. Conclusion Buckwheat mosaic flavonoids have protective effects on myocardial hypertrophy in rats, and its mechanism may be related to the antagonism of myocardial local renin-angiotensin (RAS) system.